---
title: "Pomerantz LLP Notifies Investors of Class Action Against Cytokinetics, Incorporate – CYTK"
description: "Pomerantz LLP has filed a class action lawsuit against Cytokinetics, Inc. for alleged securities fraud and unlawful business practices. Investors who purchased Cytokinetics securities during the Class"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260792363.md"
published_at: "2025-10-12T15:00:09.000Z"
---

# Pomerantz LLP Notifies Investors of Class Action Against Cytokinetics, Incorporate – CYTK

> Pomerantz LLP has filed a class action lawsuit against Cytokinetics, Inc. for alleged securities fraud and unlawful business practices. Investors who purchased Cytokinetics securities during the Class Period are encouraged to contact the firm by November 17, 2025, to be appointed as Lead Plaintiff. The lawsuit follows significant stock price drops after Cytokinetics disclosed issues with its New Drug Application for aficamten, including the FDA's decision not to convene an advisory committee and the omission of a Risk Evaluation and Mitigation Strategy in the original filing.

NEW YORK CITY, NY / ACCESS Newswire / October 12, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate ("Cytokinetics" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Cytokinetics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 17, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Cytokinetics securities during the Class Period. A copy of the Complaint can be obtained at **www.pomerantzlaw.com****.**

\[Click here for information about joining the class action\]

On March 10, 2025, Cytokinetics disclosed that the U.S. Food and Drug Administration ("FDA") had decided not to convene an advisory committee meeting to review the Company's New Drug Application ("NDA") for aficamten. On May 1, 2025, Cytokinetics announced that the FDA had extended the Prescription Drug User Fee Act action date for aficamten's NDA from September 26, 2025 to December 26, 2025 in order to review a Risk Evaluation and Mitigation Strategy ("REMS") submitted at the FDA's request after the initial NDA filing, thereby disclosing that the Company had not included a REMS in the original NDA.

On this news, Cytokinetics' stock price fell $5.57 per share, or 12.98%, to close at $37.35 per share on May 2, 2025.

Then, on May 6, 2025, Chief Executive Officer Robert I. Blum acknowledged that Cytokinetics had multiple pre-NDA meetings with the FDA to discuss safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials.

On this news, Cytokinetics' stock price fell $2.70 per share, or 7.36%, to close at $33.97 per share on May 6, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

**SOURCE:** Pomerantz LLP

View the original press release on ACCESS Newswire

### Related Stocks

- [CYTK.US - Cytokinetics](https://longbridge.com/en/quote/CYTK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 細胞動力（CYTK）的看漲理由可能會因 MYQORZO 的進展和 HCM 倡導資助的變化而發生改變 | Cytokinetics 已向肥厚型心肌病 (HCM) 倡導組織提供了資助，並確認了 MYQORZO (aficamten) 在症狀性梗阻性 HCM 中的批准，該藥物正在歐盟審查中。這一進展支持了公司專注於疾病意識和患者參與的商業戰略。儘管 | [Link](https://longbridge.com/en/news/275682572.md) |
| 細胞動力的一位高管通過出售內部股票做出了重大舉動 | Cytokinetics 的執行副總裁兼首席商業官 Andrew Callos 於 2026 年 1 月 2 日出售了 1,798 股，價值 112,584 美元，顯示出顯著的內部交易活動。這一消息是在 FDA 批准 aficamten（M | [Link](https://longbridge.com/en/news/271378716.md) |
| $HUBG 法律通知：樞紐集團公司因財務重述面臨證券欺詐調查 | Hub Group Inc. 正在接受 Bleichmar Fonti & Auld LLP 的調查，原因是可能違反了與財務重述相關的聯邦證券法。此次調查是在 Hub Group 於 2026 年 2 月 5 日宣佈將推遲發佈 2025 年 | [Link](https://longbridge.com/en/news/275940584.md) |
| ETDOOR 投資者有機會主導美森耐特國際公司證券欺詐訴訟 | 羅森律師事務所宣佈對在 2023 年 6 月 5 日至 2024 年 2 月 8 日期間出售梅森國際公司（NYSE: DOOR）普通股的投資者提起集體訴訟。投資者可能有權獲得賠償，無需預付費用。訴訟指控在歐文斯科寧收購梅森股票的提議中存在重 | [Link](https://longbridge.com/en/news/276086471.md) |
| uniQure N.V.的投資者有機會主導證券欺詐訴訟 | 羅森律師事務所已宣佈對在 2025 年 9 月 24 日至 2025 年 10 月 31 日期間購買 uniQure N.V.（NASDAQ: QURE）股票的投資者提起集體訴訟。投資者可能有權獲得無需預付費用的賠償。訴訟聲稱 uniQur | [Link](https://longbridge.com/en/news/276158425.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.